



# Biotech Daily

Monday June 21, 2021

*Daily news on ASX-listed biotechnology companies*

## Actinogen Appoints 2 CROs, Cogstate For Xanamia

### [ACTINOGEN MEDICAL](#)

Actinogen says it has appointed two clinical research organisations and Cogstate to assist in the conduct, management, and recruitment of the Xanamia part-A study.

Earlier this month, Actinogen said it had ethics approval for its 100-healthy older volunteer, part-A Xanamia dosing study of Xanamem for cognition (BD: Jun 2, 2021).

Today, the company said that Sydney's Paratus Clinical and Adelaide's Avance Clinical would assist the study, costing a total of about \$2.1 million.

Actinogen said it had an agreement with Cogstate for \$US300,000 (\$A399,474) to use its cognition tests.

The company said the dose ranging Xanamia study would be conducted at four Paratus Clinics enrolling 105 healthy volunteers aged 50 years and above, to confirm the minimum effective dose, while Avance would manage the study.

Actinogen was up 2.5 cents or 19.2 percent to 15.5 cents with 20.5 million shares traded.

**Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053**  
email: [editor@biotechdaily.com.au](mailto:editor@biotechdaily.com.au); [www.biotechdaily.com.au](http://www.biotechdaily.com.au); twitter: [@biotech\\_daily](https://twitter.com/biotech_daily)